COVID-19 pneumonia and tocilizumab use

Cáceres-Bernaola U.; Becerra-Núñez C.; de Tai S.M.-T.; Ravelo-Hernández J. · Anales de la Facultad de Medicina (2020) · DOI: 10.15381/anales.v81i2.17893

Resumen

We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interleukin-6 receptor antagonist (tocilizumab) for compassionate use, obtaining a favorable clinical response.